200 related articles for article (PubMed ID: 8837610)
1. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection.
Whittum-Hudson JA; An LL; Saltzman WM; Prendergast RA; MacDonald AB
Nat Med; 1996 Oct; 2(10):1116-21. PubMed ID: 8837610
[TBL] [Abstract][Full Text] [Related]
2. The anti-idiotypic antibody to chlamydial glycolipid exoantigen (GLXA) protects mice against genital infection with a human biovar of Chlamydia trachomatis.
Whittum-Hudson JA; Rudy D; Gèrard H; Vora G; Davis E; Haller PK; Prattis SM; Hudson AP; Saltzman WM; Stuart ES
Vaccine; 2001 Jul; 19(28-29):4061-71. PubMed ID: 11427283
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and functional antigenic mimicry by a polyclonal anti-idiotypic antibody for chlamydial exoglycolipid antigen.
An LL; Hudson AP; Prendergast RA; O'Brien TP; Stuart ES; Whittum-Hudson JA; MacDonald AB
Pathobiology; 1997; 65(5):229-40. PubMed ID: 9459493
[TBL] [Abstract][Full Text] [Related]
4. Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies.
Badamchi-Zadeh A; McKay PF; Holland MJ; Paes W; Brzozowski A; Lacey C; Follmann F; Tregoning JS; Shattock RJ
PLoS One; 2015; 10(10):e0141209. PubMed ID: 26501198
[TBL] [Abstract][Full Text] [Related]
5. A chlamydial major outer membrane protein extract as a trachoma vaccine candidate.
Campos M; Pal S; O'Brien TP; Taylor HR; Prendergast RA; Whittum-Hudson JA
Invest Ophthalmol Vis Sci; 1995 Jul; 36(8):1477-91. PubMed ID: 7601629
[TBL] [Abstract][Full Text] [Related]
6. Towards a Chlamydia trachomatis vaccine: how close are we?
Cochrane M; Armitage CW; O'Meara CP; Beagley KW
Future Microbiol; 2010 Dec; 5(12):1833-56. PubMed ID: 21155665
[TBL] [Abstract][Full Text] [Related]
7. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.
Murthy AK; Chambers JP; Meier PA; Zhong G; Arulanandam BP
Infect Immun; 2007 Feb; 75(2):666-76. PubMed ID: 17118987
[TBL] [Abstract][Full Text] [Related]
8. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine.
Kari L; Whitmire WM; Crane DD; Reveneau N; Carlson JH; Goheen MM; Peterson EM; Pal S; de la Maza LM; Caldwell HD
J Immunol; 2009 Jun; 182(12):8063-70. PubMed ID: 19494332
[TBL] [Abstract][Full Text] [Related]
9. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection.
Su H; Parnell M; Caldwell HD
Vaccine; 1995 Aug; 13(11):1023-32. PubMed ID: 8525685
[TBL] [Abstract][Full Text] [Related]
10.
Shillova N; Howe SE; Hyseni B; Ridgell D; Fisher DJ; Konjufca V
Infect Immun; 2020 Dec; 89(1):. PubMed ID: 33139380
[No Abstract] [Full Text] [Related]
11. A Role for the glycolipid exoantigen (GLXA) in chlamydial infectivity.
Vora GJ; Stuart ES
Curr Microbiol; 2003 Mar; 46(3):217-23. PubMed ID: 12567246
[TBL] [Abstract][Full Text] [Related]
12. Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines.
Finco O; Frigimelica E; Buricchi F; Petracca R; Galli G; Faenzi E; Meoni E; Bonci A; Agnusdei M; Nardelli F; Bartolini E; Scarselli M; Caproni E; Laera D; Zedda L; Skibinski D; Giovinazzi S; Bastone R; Ianni E; Cevenini R; Grandi G; Grifantini R
Proc Natl Acad Sci U S A; 2011 Jun; 108(24):9969-74. PubMed ID: 21628568
[TBL] [Abstract][Full Text] [Related]
13. Vaccines against Chlamydia: approaches and progress.
Stagg AJ
Mol Med Today; 1998 Apr; 4(4):166-73. PubMed ID: 9572058
[TBL] [Abstract][Full Text] [Related]
14. Attempted oral immunization with chlamydial lipopolysaccharide subunit vaccine.
Taylor HR; Prendergast RA
Invest Ophthalmol Vis Sci; 1987 Oct; 28(10):1722-6. PubMed ID: 3308760
[TBL] [Abstract][Full Text] [Related]
15. Oral immunization with chlamydial major outer membrane protein (MOMP).
Taylor HR; Whittum-Hudson J; Schachter J; Caldwell HD; Prendergast RA
Invest Ophthalmol Vis Sci; 1988 Dec; 29(12):1847-53. PubMed ID: 3192374
[TBL] [Abstract][Full Text] [Related]
16. A peptide of Chlamydia trachomatis shown to be a primary T-cell epitope in vitro induces cell-mediated immunity in vivo.
Knight SC; Iqball S; Woods C; Stagg A; Ward ME; Tuffrey M
Immunology; 1995 May; 85(1):8-15. PubMed ID: 7543450
[TBL] [Abstract][Full Text] [Related]
17. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae.
Su H; Messer R; Whitmire W; Fischer E; Portis JC; Caldwell HD
J Exp Med; 1998 Sep; 188(5):809-18. PubMed ID: 9730883
[TBL] [Abstract][Full Text] [Related]
18. A novel approach to the laboratory diagnosis of Chlamydia trachomatis infections using monoclonal anti-idiotypic antibodies.
Laferrière C; Peeling RW; Tackaberry ES; Hamel J; Dillon JA; Brodeur BR
J Immunol Methods; 1993 Jul; 163(1):123-31. PubMed ID: 8101547
[TBL] [Abstract][Full Text] [Related]
19. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis.
Lu H; Xing Z; Brunham RC
J Immunol; 2002 Dec; 169(11):6324-31. PubMed ID: 12444139
[TBL] [Abstract][Full Text] [Related]
20. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection.
Singh SR; Hulett K; Pillai SR; Dennis VA; Oh MK; Scissum-Gunn K
Vaccine; 2006 Feb; 24(8):1213-24. PubMed ID: 16194585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
